Research map: Universally offered germline testing in upper tract urothelial carcinoma

Back to the article

Papers in this map

  1. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies · Erik B von Elm · 2007 · 10808 citations · Cited by this paper
  2. Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size–dependent survival in pT3N0M0 clear cell renal cell carcinoma · 2026 · Related
  3. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer · Thierry André · 2020 · 3141 citations · Cited by this paper
  4. Sex-based differences in peri-operative and long-term oncologic outcomes after primary surgical treatment for kidney cancer: A comprehensive analysis from a high-volume tertiary center · 2026 · Related
  5. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC☆ · Hans F. A. Vasen · 1999 · 2531 citations · Cited by this paper
  6. Automated algorithm for surgical outcomes abstraction for cystectomy · 2026 · Related
  7. ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes · Sapna Syngal · 2015 · 1676 citations · Cited by this paper
  8. Post-treatment diffusion MRI–derived apparent diffusion coefficient as a biomarker of response and prognosis following definitive radiotherapy for prostate cancer: Impact of focal dose escalation on ADC dynamics · 2026 · Related
  9. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer · Andrea Cercek · 2022 · 1659 citations · Cited by this paper
  10. Beyond PSA90: Deep PSA response predicts outcomes in nonmetastatic CRPC · 2026 · Related
  11. Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteria · Keith Nykamp · 2017 · 783 citations · Cited by this paper
  12. Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study · 2026 · Related
  13. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database · Mev Dominguez–Valentin · 2019 · 682 citations · Cited by this paper
  14. Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study · 2026 · Related
  15. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer · Alicia J. Latham · 2018 · 637 citations · Cited by this paper
  16. Featured SUO Fellow: Parth Thakker, MD · 2026 · Related
  17. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database · Pål Møller · 2017 · 591 citations · Cited by this paper
  18. Identification and validation of TP53/p53 status as a prognostic marker in penile squamous cell carcinoma: Evidence from a cohort study and meta-analysis · 2026 · Related
  19. Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment · Allison W. Kurian · 2014 · 495 citations · Cited by this paper
  20. Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio · 2026 · Related
  21. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome · Niloy Jewel Samadder · 2020 · 310 citations · Cited by this paper
  22. Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome · Fay Kastrinos · 2017 · 170 citations · Cited by this paper
  23. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications · Henry T. Lynch · 2006 · 165 citations · Cited by this paper
  24. Cancer Susceptibility Mutations in Patients With Urothelial Malignancies · Maria Isabel Carlo · 2019 · 150 citations · Cited by this paper
  25. Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers · Wenche Sjursen · 2010 · 102 citations · Cited by this paper
  26. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study · Pedro Luiz Serrano Usón · 2021 · 86 citations · Cited by this paper
  27. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma · Michael Metcalfe · 2017 · 80 citations · Cited by this paper
  28. Molecular testing for endometrial cancer: An SGO clinical practice statement · Christine Walsh · 2022 · 64 citations · Cited by this paper
  29. Unexpected expression of mismatch repair protein is more commonly seen with pathogenic missense than with other mutations in Lynch syndrome · Wei Chen · 2020 · 38 citations · Cited by this paper
  30. Genetic Referral Patterns and Responses to Clinical Scenarios: A Survey of Primary Care Providers and Clinical Geneticists · Tina K. Truong · 2021 · 38 citations · Cited by this paper
  31. Comprehensive analysis of germline drivers in endometrial cancer · Sushmita Gordhandas · 2023 · 22 citations · Cited by this paper
  32. Immunohistochemical Screening of Upper Tract Urothelial Carcinomas for Lynch Syndrome Diagnostics: A Systematic Review · Maria Rasmussen · 2022 · 21 citations · Cited by this paper
  33. Gender-specific counselling of patients with upper tract urothelial carcinoma and Lynch syndrome · Clara Cerrato · 2023 · 14 citations · Cited by this paper
  34. Survival Outcomes by Race Following Surgical Treatment for Upper Tract Urothelial Carcinoma · Jason L. Zappia · 2024 · 13 citations · Cited by this paper
  35. Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors · Maria Rasmussen · 2023 · 12 citations · Cited by this paper
  36. Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study · Mouneeb M. Choudry · 2024 · 12 citations · Cited by this paper
  37. Cancer risks for MSH6 pathogenic variant carriers · A. Lam · 2025 · 6 citations · Cited by this paper
  38. Immune checkpoint inhibitors (ICIs) in advanced upper tract urothelial cancer (UTUC) with mismatch repair deficiency (dMMR) or microsatellite instability (MSI). · Mohammad Jad Moussa · 2025 · 3 citations · Cited by this paper
  39. Estimating the prevalence of germline mutations in DNA mismatch repair genes among patients with upper tract urothelial carcinoma: a systematic review and meta-analysis · Joseph Moryousef · 2026 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)